TRALOKINUMAB Pharmacologic Class Indexing

Class set ID
2eb3876e-214e-418f-a7d5-e114160d3efa
Version
1
Effective date
20220322
Type
Indexing - Pharmacologic Class

Mapped DailyMed Labels#

Label, Manufacturer, Effective table
LabelManufacturerEffectiveSPL version
These highlights do not include all the information needed to use ADBRY safely and effectively. See full prescribing information for ADBRY. ADBRY ® (tralokinumab-ldrm) injection, for subcutaneous use Initial U.S. Approval: 2021LEO Pharma Inc. | Catalent Indiana, LLC. | Astra Zeneca Pharmaceuticals LP | LEO Pharma A/S2025121715